Omezalin (Omeprazole)

Omeprazole, the active ingredient in Omezalin, is a proton pump inhibitor presented as a 20 mg tablet for oral use. It reduces stomach acid production and is used to treat gastro‑intestinal reflux disease and ulcers in adults and children. GNH USA supplies Omezalin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omezalin is a proton pump inhibitor that acts on the acid‑secretion pathway in the stomach. It is indicated for several gastrointestinal conditions: - Gastro‑esophageal reflux disease (GERD): alleviates heartburn and promotes healing of the esophageal lining. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the disorder.

Adverse reactions to Omezalin are generally mild to moderate and vary with duration of therapy.

Common Side Effects: - Headache: mild, transient headache. - Diarrhea: loose stools without blood. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Acute interstitial nephritis: kidney inflammation with reduced urine output. - Hypomagnesemia: low serum magnesium causing muscle cramps. - Stevens‑Johnson syndrome: severe skin rash and mucosal involvement. - Liver enzyme elevation: increased ALT/AST levels indicating hepatic stress.

When prescribing Omezalin, clinicians should consider several safety aspects: - Renal impairment: adjust monitoring if kidney function is reduced. - Hepatic impairment: use with caution in patients with liver disease. - Long‑term use: assess need for periodic vitamin B12 monitoring. - Drug‑induced osteoporosis risk: evaluate calcium and vitamin D status during extended therapy. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed. - Store at ambient temperature: keep below 25 °C, retain original packaging, and protect from moisture.

Omeprazole may affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular event risk. - Atazanavir: decreased antiviral exposure, compromising HIV therapy. - Methotrexate: heightened toxicity due to reduced renal clearance.

Moderate Interactions (Monitor Closely): - Warfarin: potential INR elevation; monitor coagulation parameters. - Digoxin: possible increase in serum levels; check cardiac status. - Phenytoin: altered metabolism may change seizure control. - Ketoconazole: reduced antifungal absorption; consider alternative agents.